[49] In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo
Understanding what is in your vial, and why, allows you to make informed decisions and to recognize if a formulation switch is warranted
References: OnceWeekly Semaglutide in Adults with Overweight or Obesity (STEP1 Trial), New England Journal of Medicine, 2021, Because semaglutide is a prescription medication, treatment should always be initiated and monitored by a qualified healthcare professional who can determine the appropriate dosage and assess whether the therapy is suitable for a particular patient
For injection site reactions, patient education on proper injection technique is foundational